INTRODUCTION
Biomarkers are characteristic biological properties that can be detected and measured in a variety of biological matrices in the human body, including the blood, urine and tissue, to give an indication of whether there is a threat of disease, if a disease already exists, or how such a disease may develop in an individual case [1] . The definition of a biomarker has been expanded to include pharmacologic responses to therapeutic intervention by the Biomarkers Consortium (http://www.biomarkersconsor-tium.org).
Molecular epidemiology is a branch of epidemiology that uses biomarkers to deal with the contribution of potential genetic and environmental risk factors identified at the molecular level, to the etiology, distribution and control of the disease in human populations. Since the phrase molecular epidemiology was formalized in the first book by Schulte and Perera [1] , molecular epidemiology has improved our understanding of specific pathways, molecules and susceptibility genes that influence the risk of developing disease.
With the completion of the Human Genome Project [2] and the HapMap Project (www.hapmap.org, 2005), genomic epidemiology (also known as, human genome epidemiology) has been established as an evolving field of inquiring that uses the systematic application of epidemiologic methods and approaches in population-based studies of the impact of human genetic variation on health and disease (http://www. cdc.gov/genomics/hugenet) [3] . Molecular epidemiology, in its broader definition, includes the scope of human genome epidemiology, which focuses on genetic variation, one type of biomarker, and its interaction with environmental risk factors in the development of human disease. With the recent advance of various types of highthroughput technology in the area of genomics, epigenomics, and proteomics, the scope of molecular epidemiology and genomic epidemiology has expanded rapidly.
In this review, issues in evaluating biomarkers will be discussed, and biomarkers of environmental exposure, early biologic effect, and susceptibility identified and validated in epidemiological studies will be summarized. The spectrum of genomic approaches to identify and apply biomarkers and strategies to validate genomic biomarkers is then discussed.
CLASSIFICATION OF BIO-MARKERS
In molecular epidemiology, biomarkers have usually been classified into three categories: exposure, effect (disease), and susceptibility [3] 
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Kyoung-Mu Lee 1, 2) , Sohee Han 2) , Woong-Yang Park ( Figure 1 ). Along the continuum from biomarkers of exposure to clinical disease and progression, exposure, internal dose, biologically effective dose, early biologic effect, altered structure and/or function, clinical disease, and disease progression can potentially be observed and quantified. Biomarkers of exposure include exogenous chemicals or metabolite(s), internal dosimeters of the chemical or metabolite concentrations and biologically effective doses. These markers may integrate multiple portals of entry and fluctuating exposures, and relate the time of exposure to the internal dose [4] . Biomarkers of exposure are important in biological monitoring, because they may be an indicator of internal dose, or the amount of chemical exposure into the body. Significant advances have been made in the development of analytical methods which can detect and/or quantify the presence of many natural or synthetic toxins or their breakdown products (metabolites) in a biological matrix (such as blood or urine). It is note worthy that a adequate understanding of the chemistry and toxicology of the substance under consideration is required to measure biomarkers of exposure accurately.
Biomarkers of effects include the measurable alterations of an organism that can indicate a potential or established health impairment or disease (e.g., blood pressure, cholesterol levels and viral load in HIV). Markers of altered structure and/or function are useful for assessing morphological and/or functional changes following toxicant-cell interactions. Recently, a number of studies were conducted to discover biomarkers for prognosis as well as diagnosis; thus, biomarkers of prognosis may be considered as a separate category.
Biomarkers of susceptibility are indicators of inherent or acquired properties that may lead to an increase in the internal dose of a chemical or an increased level of the response resulting from environmental exposure. Examples of susceptibility biomarkers are polymorphisms in genes involved in carcinogen metabolism or DNA repair [5] [6] .
EVALUATION OF BIOMAR-KERS
In order to be useful, biomarkers must be rigorously tested prior to application in risk assessment, disease diagnosis and predictions of prognosis. Given that the combination of a number of factors limits useful applications of biomarkers, we summarized the general criteria that should be taken into account when evaluating biomarkers.
I. Biological Relevance
A useful biomarker needs to have biological relevance. Typically, limited information is available regarding where the markers are located along the multi-step pathway of human disease. Evidence from experimental studies (in vitro and in vivo) on exposure-effect relationships can sometimes provide certain levels of insight into the evaluation of biomarkers [7] .
II. Biological Sample and Assay
An easily attainable sample is one that can be obtained with limited stringency of preparation.
Urine is one of readily useable samples in a non-invasive way, and blood can be a good source for biomarker information because it is exposed directly to all organs of the body. Therefore urine and blood samples are collected by almost all ongoing prospective cohort studies.
The detection method for a biomarker must be accurate, rapid and as easy to carry out as possible. Levels of exposures and biomarkers may be below the analytical limits of detection.
The results from different laboratories should not differ significantly from each other. Reliability is often described as the coefficient of variation between repeated measurements of the same samples.
Determining the specificity and sensitivity are critical components of the evaluation process of biomarkers. Specificity refers to the ability of a measurement to identify negative responses effectively in order to minimize the number of false positives, while sensitivity refers to the ability of a measurement to detect positive responses. A biomarker observed well before the onset of disease may have a low predictive value as a biomarker of effect but may be very useful as a biomarker of exposure, enabling long-term surveillance of an exposed population. In contrast, a biomarker of effect that is expressed long after exposure could be of relatively little use in exposure assessment whereas it may be very useful in calculating risk of disease and predicting the progression.
III. Population and Clinical Validity
Factors related to the population validity of biomarkers include the frequency or prevalence of the biomarkers, greater interindividual variation than intra-individual variation, potential confounders, and invasiveness of specimen collection [7] . Information on conditions under which samples were collected, stored, and analyzed (e.g., fasting status, season of blood sampling, batch of the assay, differential handling of specimens from cases and control, etc.) is also metabolomics has opened new windows to study disease etiology and prognosis.
SPECTRUM OF GENOMIC BIOMARKERS
Although DNA microarray technologies were launched initially to analyze mRNA, other powerful tools for global analyses of cellular constituents are now available. These include technologies for global analyses of polymorphisms and proteins [23] , and cellular metabolites [24] . The use of proteomic and metabolomic tools in combination with genomic techniques will be important for obtaining a comprehensive picture of physiological and pathological changes in cell, tissue and organs.
I. Single Nucleotide Polymorphism (SNP)
In addition to the study of gene expression/ proteins/metabolites, identification of gene sequence variation (polymorphisms) is also available in a microarray format. Such methods are making possible systematic evaluations of the effects of common genetic variants or treatments [25] . Examples of genetic variants
GENOMIC APPROACHES TO IDENTIFY AND APPLY BIOMARKERS
A paradigm shift has recently been realized, whereby single-biomarker analysis is being replaced by multiparametric analyses of genes or proteins [17] . Various genomics-based approaches are being successfully used to identify and apply biomarkers in molecular and genomic epidemiology. Until recently, the discovery of cancer biomarkers has been a slow approach to identify proteins that are dysregulated as a consequence of the disease and shed into body fluids such as serum, urine, or saliva [18] . The recent advancements in genomic and proteomic technologies including gene array technology coupled with advancements in bioinformatics tools, shows great promise of meeting the demand for the discovery of a variety of new biomarkers that are both sensitive and specific.
Genomic approaches could unseal the molecular mechanisms or biological pathways of various physiological conditions [19, 20] as well as human diseases [21, 22] . Molecular profiling via genomics, proteomics, and important [16] . This information can possibly be used for adjustment or stratification in the statistical analysis in order to minimize measurement error.
In clinical settings, biomarkers must to be evaluated in terms of validity in diagnosis and prognosis. Based on the evaluation, appropriate and effective clinical intervention can be pursued through early diagnosis and intervention.
BIOMARKERS VALIDATED IN EPIDEMIOLOGICAL STUDIES
Validation of biomarkers is a lengthy process that takes years of laboratory work and interlaboratory collaborations. Well-defined biomarkers that are ultimately used in risk appraisal and in the clinics are likely to be in small numbers. Only a few biomarkers related to research on cancer have been validated in prospective cohort studies.
Selected biomarkers of exposure, early biologic effect, and susceptibility evaluated and validated in epidemiological studies are listed in Table 1, Table 2, and Table 3 , respectively. Van et al., [8] Van et al., [9] that affect the sensitivity to drugs and cancer prognosis have long been known. High throughput genotyping of SNPs is now revealing a growing number of disease susceptibility genes [39, 40] , as well as polymorphisms that determine individual diversity in drug responses [41] .
II. Copy Number Variation
The copy number variant (CNV) is the variable number of copies of a particular gene or segment of DNA and involves as much as 12% of human genome [42] . Studies of the human genome have revealed an unsuspected amount of variation between people in the number of copies of genes they have. Recent evidence shows that the gene copy number can be elevated in cancer cells. Because extra copies of DNA segment can cause disease, scientists should consider CNVs together with mutations or SNPs when seeking genetic causes for the response to chemicals. Bonassi et al., [26] Anttila et al., [27] Duffy et al., [28] Rinaldi et al., [29] Tokuhisa et al., [30] Weitzel et al., [31] III. Epigenetic Change of DNA DNA methylation is a type of chemical modification of DNA that can be inherited and subsequently removed without changing the original DNA sequence. DNA methylation involves the addition of a methyl group to DNA with the specific effect of reducing gene expression; It typically occurs in a CpG dinucleotide context in the 5 regulatory regions of many genes. Alterations of DNA methylation have been recognized as an important component of diseases including cancer [43] .
Adductomics is the study of DNA adducts in an entire genome. DNA adducts are compounds bound to DNA, causing damage and mutations. Cellular DNA is always exposed to various DNA damaging agents such as UV light, ionizing radiation and environmental carcinogens. Endogenous reactive oxygen species, reactive nitrogen species and lipid peroxide also cause DNA damage. The science of adductomics seeks to identify all DNA adducts and the target sequence of each adduct.
IV. Transcriptome
Given a number of diseases generally involves changes in a series of gene expression and their interactions, a global analysis of gene expression (i.e., microarray) may provide a more comprehensive view of human diseases [44] . Gene expression is altered either directly or indirectly as a result of environmental exposure (e.g., ionizing radiation) [45] . The promising fields of microarray technology include identification of specific biomarkers for the monitoring of disease progression and prognosis as well as gene-environment interaction [46, 47] . As a new genomic biomarker, the genome-wide profiling of the microRNAs may be a more powerful tool to find early detection markers for cancer [48] .
V. Proteome
Proteomics is a global analysis of the full set of proteins (the proteome) of a tissue or cell type encoded by a genome and deals with separation, quantitation and functional characterization of expressed proteins in biological samples [49] . The most commonly used techniques for studying the proteome are two-dimensional (2D) gel electrophoresis and mass spectrometry. Recently, new proteomic technologies such as multi-dimensional protein identification technology [50] and specific protein and antibodies arrays [51] have allowed the genome-wide functional and structural characterization of proteins.
Profiling of global protein expression patterns provides important complementary information to genomics, as RNA is subject to posttranscriptional control to regulate the amount and quality of proteins i.e., phosphorylation, ubiquitination and other process). Thus, proteomic technology may offer better knowledge of the cellular process along with complementary information to genomics.
VI. Metabolome
Metabolome refers to the complete set of small-molecule metabolites including metabolic intermediates and secondary metabolites that are found in biological samples [52] . Metabolomics combines the application of analytical technologies (e.g., mass spectro-metry and nuclear magnetic resonance spectrometry) with statistics and bioinformatics to allow the quantitative measurement of the levels of cellular metabolites [53] .
While it is quite difficult to extract cellular mRNA and protein from limited amounts of tissues, metabolites can be easily purified from tissue as well as fluids such as serum, plasma, cerebrospinal fluids and urine.
IDENTIFICATION AND VALI-DATION OF GENOMIC BIO-MARKERS
Despite the current optimism related to genomic approaches, a number of important limitations to the discovery of novel single biomarkers have been suggested, including study design bias, artifacts related to the collection and storage of samples, and falsepositive results [17] .
The development of various emerging biomarkers might be considered as a process similar to therapeutic drug development; Figure 2 shows the overall procedures used in the identification and application of genomic biomarkers. In the discovery (screening) stage, up to hundreds of thousands of genomic markers should be identified from the analyses of a small number of very well-characterized samples such as cancers, pre-cancers or normal tissue specimens. Prior to further evaluation, other information such as gene expression patterns may help to prioritize candidates for further evaluation. Hundreds of candidates are subjected to an iterative process of verification and assay development in which highly sensitive, targeted analyses replicate the results. The final stage of the procedure is an evaluation of biomarker candidates in populations or clinical trials. A few highly promising biomarker candidates may remain for evaluation by this stage.
As a means of increasing the efficiency, Integrative Functional Informatics represents a novel direction; The interfacing and integration of different technologies for data collection and analysis are expected to be pivotal to biomarker identification, characterization, validation and application [54, 55] .
CONCLUSION
In this review, we briefly summarized issues in evaluating biomarkers and selected cancer biomarkers that were validated in epidemiological studies. We also discussed genomic biomarkers as a new approach to identify and apply biomarkers. We note that the utility and importance of biomarkers has been well recognized and that biomarker discovery efforts are now common in both academic and industrial settings. Research on the discovery and development of biomarkers is expected to shift toward a more organized and integrative approach with technological advances in molecular and genomic epidemiology.
